Seagen Inc (NASDAQ:SGEN)
| 140.66 Delayed Data As of 3:59pm ET |  +0.97 / +0.69%Today’s Change | 105.43 Today|||52-Week Range 183.00 | +9.45% Year-to-Date |
Latest SGEN News | Press Releases
| Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication Jan 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 139.69 |
| Today’s open | 139.69 |
| Day’s range | 138.95 - 141.02 |
| Volume | 19,549 |
| Average volume (3 months) | 951,013 |
| Market cap | $24.4B |
Data as of 3:59pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -205.55% |
| Earnings growth (this year) | +4.46% |
| Earnings growth (next 5 years) | +23.00% |
| Revenue growth (last year) | -27.63% |
| P/E ratio | NM |
| Price/Sales | 17.88 |
| Price/Book | 7.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | -0.62 | -0.56% |
| ALNYAlnylam Pharmaceutic... | -0.11 | -0.05% |
| ---- | ||
| INCYIncyte Corp | -0.37 | -0.43% |
Data as of 3:59pm ET, 01/27/2023
Financials
| Next reporting date | February 16, 2023 |
| EPS forecast (this quarter) | -$1.01 |
| Annual revenue (last year) | $1.6B |
| Annual profit (last year) | -$674.5M |
| Net profit margin | -42.84% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bothell, Washington |
Forecasts
